Intranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice
Open Access
- 7 June 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Virology Journal
- Vol. 10 (1), 183-8
- https://doi.org/10.1186/1743-422x-10-183
Abstract
Background Human respiratory syncytial virus (RSV) is a serious pediatric pathogen of the lower respiratory tract. Currently, there is no clinically approved vaccine against RSV infection. Recent studies have shown that helper-dependent adenoviral (HDAd) vectors may represent effective and safe vaccine vectors. However, viral challenge has not been investigated following mucosal vaccination with HDAd vector vaccines. Methods To explore the role played by HDAd as an intranasally administered RSV vaccine vector, we constructed a HDAd vector encoding the codon optimized fusion glycoprotein (Fsyn) of RSV, designated HDAd-Fsyn, and delivered intranasally HDAd-Fsyn to mice. Results RSV-specific humoral and cellular immune responses were generated in BALB/c mice, and serum IgG with neutralizing activity was significantly elevated after a homologous boost with intranasal (i.n.) application of HDAd-Fsyn. Humoral immune responses could be measured even 14 weeks after a single immunization. Immunization with i.n. HDAd-Fsyn led to effective protection against RSV infection on challenge. Conclusion The results indicate that HDAd-Fsyn can induce powerful systemic immunity against subsequent i.n. RSV challenge in a mouse model and is a promising candidate vaccine against RSV infection.Keywords
This publication has 23 references indexed in Scilit:
- Assembly and Immunological Properties of Newcastle Disease Virus-Like Particles Containing the Respiratory Syncytial Virus F and G ProteinsJournal of Virology, 2011
- Biological challenges and technological opportunities for respiratory syncytial virus vaccine developmentImmunological Reviews, 2010
- A prime–boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virusBiochemical and Biophysical Research Communications, 2010
- Protective Efficacy and Immunogenicity of an Adenoviral Vector Vaccine Encoding the Codon-Optimized F Protein of Respiratory Syncytial VirusJournal of Virology, 2009
- Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus VaccinesViruses, 2009
- Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c miceBiochemical and Biophysical Research Communications, 2009
- Comparison of Replication-Competent, First Generation, and Helper-Dependent Adenoviral VaccinesPLOS ONE, 2009
- Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and DJournal of Virology, 2007
- Age Dependence of Adenovirus-Specific Neutralizing Antibody Titers in Individuals from Sub-Saharan AfricaJournal of Clinical Microbiology, 2006
- Identification of a Recombinant Live Attenuated Respiratory Syncytial Virus Vaccine Candidate That Is Highly Attenuated in InfantsThe Journal of Infectious Diseases, 2005